Medical Xpress·3 min read·medium
Drug candidate could help L-dopa work better for patients with Parkinson's
U
University of California - San Diego
✦AI Summary
A startup called Sinopia Biosciences has developed a drug candidate, SB-0110, that aims to enhance the effectiveness of L-dopa for Parkinson's patients while reducing side effects like dyskinesia. Preclinical results published in Science Translational Medicine show promise for this dual-action treatment.
edited by Sadie Harley , reviewed by Andrew Zinin
healthsciencestartups
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in